Maia Biotechnology Inc (MAIA)

$3.06

+0.18

(+6.25%)

Market is closed - opens 8 PM, 06 Nov 2024

Performance

  • $2.95
    $3.20
    $3.06
    downward going graph

    3.76%

    Downside

    Day's Volatility :7.97%

    Upside

    4.38%

    downward going graph
  • $0.82
    $5.99
    $3.06
    downward going graph

    73.2%

    Downside

    52 Weeks Volatility :86.31%

    Upside

    48.91%

    downward going graph

Returns

PeriodMaia Biotechnology IncIndex (Russel 2000)
3 Months
14.18%
0.0%
6 Months
-7.55%
0.0%
1 Year
41.67%
0.0%
3 Years
-31.39%
-27.4%

Highlights

Market Capitalization
69.0M
Book Value
$0.13
Earnings Per Share (EPS)
-1.62
Wall Street Target Price
12.63
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-107.11%
Return On Equity TTM
-559.56%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
Diluted Eps TTM
-1.62
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Maia Biotechnology Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 312.75%

Current $3.06
Target $12.63

Technicals Summary

Sell

Neutral

Buy

Maia Biotechnology Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Maia Biotechnology Inc
Maia Biotechnology Inc
19.07%
-7.55%
41.67%
-31.39%
-31.39%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-16.73%
-13.48%
-0.36%
33.18%
155.61%
Biontech Se
Biontech Se
-8.7%
18.88%
11.29%
-54.26%
538.49%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-0.55%
75.43%
58.71%
41.13%
193.04%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
11.43%
24.19%
29.58%
160.04%
155.08%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Maia Biotechnology Inc
Maia Biotechnology Inc
NA
NA
NA
0.0
-5.6
-1.07
NA
0.13
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
20.49
20.49
1.21
44.74
0.17
0.07
NA
272.04
Biontech Se
Biontech Se
160.8
NA
0.04
-2.8
-0.03
-0.02
NA
85.17
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.18
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
1.21
0.16
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Maia Biotechnology Inc
Maia Biotechnology Inc
Buy
$69.0M
-31.39%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$91.1B
155.61%
20.49
33.61%
Biontech Se
Biontech Se
Buy
$26.5B
538.49%
160.8
-18.75%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$34.8B
193.04%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$121.6B
155.08%
32.84
-4.74%

Insights on Maia Biotechnology Inc

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 58.7% return, outperforming this stock by 17.0%

Company Information

maia biotechnology, inc. is a targeted therapy, immune-oncology company, focused on development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. a privately-held company based in chicago, maia is led by a passionate, principled and highly experienced management team with significant drug development experience, committed to advancing promising agents into trials in humans clinical trials. maia’s business strategy is designed to advance a strong value proposition for its portfolio of potentially novel compounds. maia controls risk and enhances its opportunity for success by diversifying and generating this portfolio of assets with a variety of compounds with novel mechanisms of action which have potential activity in multiple tumor types. maia’s business model involves placing drug candidates in their own dedicated, r&d focused subsidiary company, which is supported by the common infrastru

Organization
Maia Biotechnology Inc
Employees
13
CEO
Dr. Vlad Vitoc M.B.A., M.D.
Industry
Miscellaneous

FAQs